GB1211
GB1211 is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
1
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
2
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
A Study to Compare Pharmacokinetics of GB1211
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
Clinical Trials (6)
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
A Study to Compare Pharmacokinetics of GB1211
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6